Short-term treatment with imetelstat sensitizes hematopoietic malignant cells to a genotoxic agent via suppression of the telomerase-mediated DNA repair process
暂无分享,去创建一个
[1] Y. Kakinoki,et al. Wilms Tumor 1 Expression at Diagnosis Correlates With Genetic Abnormalities and Polymorphism But Is Not Independently Prognostic in Acute Myelogenous Leukemia: A Hokkaido Leukemia Net Study , 2018, Clinical lymphoma, myeloma & leukemia.
[2] Zachary D Schrank,et al. Oligonucleotides Targeting Telomeres and Telomerase in Cancer , 2018, Molecules.
[3] Sunny Y. Yang,et al. Transient Telomerase Inhibition with Imetelstat Impacts DNA Damage Signals and Cell-Cycle Kinetics , 2018, Molecular Cancer Research.
[4] P. Chartrand,et al. Cell cycle–dependent spatial segregation of telomerase from sites of DNA damage , 2017, The Journal of cell biology.
[5] A. Allegra,et al. Telomerase and telomere biology in hematological diseases: A new therapeutic target. , 2017, Leukemia research.
[6] Q. Wei,et al. Telomerase antagonist imetelstat increases radiation sensitivity in esophageal squamous cell carcinoma , 2017, Oncotarget.
[7] J. Merlio,et al. Telomerase Activation in Hematological Malignancies , 2016, Genes.
[8] J. Shay,et al. Roles of telomeres and telomerase in cancer, and advances in telomerase-targeted therapies , 2016, Genome Medicine.
[9] J. Shay,et al. Role of Telomeres and Telomerase in Aging and Cancer. , 2016, Cancer discovery.
[10] R. Laborde,et al. A Pilot Study of the Telomerase Inhibitor Imetelstat for Myelofibrosis. , 2015, The New England journal of medicine.
[11] M. McDevitt,et al. Telomerase Inhibitor Imetelstat in Patients with Essential Thrombocythemia. , 2015, The New England journal of medicine.
[12] P. L. Bergsagel,et al. Repair of DNA double-strand breaks by templated nucleotide sequence insertions derived from distant regions of the genome , 2014, Proceedings of the National Academy of Sciences.
[13] V. Tergaonkar,et al. Noncanonical functions of telomerase: implications in telomerase-targeted cancer therapies. , 2014, Cancer research.
[14] Ying Yan,et al. Telomerase Inhibitor Imetelstat (GRN163L) Limits the Lifespan of Human Pancreatic Cancer Cells , 2014, PloS one.
[15] R. Pieters,et al. Telomere length and telomerase complex mutations in pediatric acute myeloid leukemia , 2012, Leukemia.
[16] Y. Kanda,et al. Investigation of the freely available easy-to-use software ‘EZR' for medical statistics , 2012, Bone Marrow Transplantation.
[17] M. Bergqvist,et al. Telomerase antagonist imetelstat inhibits esophageal cancer cell growth and increases radiation-induced DNA breaks. , 2012, Biochimica et biophysica acta.
[18] D. Baird,et al. Telomere dysfunction and its role in haematological cancer , 2012, British journal of haematology.
[19] T. Brümmendorf,et al. Leukemic fusion genes MLL/AF4 and AML1/MTG8 support leukemic self-renewal by controlling expression of the telomerase subunit TERT , 2010, Leukemia.
[20] Y. Nordenberg,et al. Telomere Shortening Sensitizes Cancer Cells to Selected Cytotoxic Agents: In Vitro and In Vivo Studies and Putative Mechanisms , 2010, PloS one.
[21] Changyu Shen,et al. The telomerase template antagonist GRN163L alters MDA-MB-231 breast cancer cell morphology, inhibits growth, and augments the effects of paclitaxel , 2009, Molecular Cancer Therapeutics.
[22] D. Gilliland,et al. Telomere length is severely and similarly reduced in JAK2V617F-positive and -negative myeloproliferative neoplasms , 2009, Leukemia.
[23] S. Kyo,et al. Understanding and exploiting hTERT promoter regulation for diagnosis and treatment of human cancers , 2008, Cancer science.
[24] J. Shay,et al. Actions of human telomerase beyond telomeres , 2008, Cell Research.
[25] A. Protopopov,et al. Telomerase inhibitor GRN163L inhibits myeloma cell growth in vitro and in vivo , 2008, Leukemia.
[26] C. Mondello,et al. Contribution of telomerase RNA retrotranscription to DNA double-strand break repair during mammalian genome evolution , 2007, Genome Biology.
[27] R. Kolodner,et al. Chromosome healing by de novo telomere addition in Saccharomyces cerevisiae , 2006, Molecular microbiology.
[28] M. Manns,et al. Telomerase antagonists GRN163 and GRN163L inhibit tumor growth and increase chemosensitivity of human hepatoma , 2005, Hepatology.
[29] C. Harley,et al. Lipid modification of GRN163, an N3′ → P5′ thio-phosphoramidate oligonucleotide, enhances the potency of telomerase inhibition , 2005, Oncogene.
[30] W. Hahn,et al. The telomerase reverse transcriptase regulates chromatin state and DNA damage responses. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[31] T. Holyoake,et al. Dysregulated expression of the major telomerase components in leukaemic stem cells , 2005, Leukemia.
[32] M. Rocchi,et al. Insertion of telomeric repeats at intrachromosomal break sites during primate evolution. , 2004, Genome research.
[33] T. Pandita,et al. Telomere stability correlates with longevity of human beings exposed to ionizing radiations. , 2003, Oncology reports.
[34] J. Shay,et al. Human Telomerase and Its Regulation , 2002, Microbiology and Molecular Biology Reviews.
[35] J. Riou,et al. Telomerase: a therapeutic target for the third millennium? , 2000, Critical reviews in oncology/hematology.
[36] J. Shay,et al. A survey of telomerase activity in human cancer. , 1997, European journal of cancer.
[37] I. Weissman,et al. Telomerase activity in hematopoietic cells is associated with self-renewal potential. , 1996, Immunity.
[38] C B Harley,et al. Specific association of human telomerase activity with immortal cells and cancer. , 1994, Science.